| Biomarker ID | 280 |
| PMID | 18543251 |
| Year | 2008 |
| Biomarker | Golgi phosphoprotein 2 (GOLPH2) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer(3.04 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-TGF-beta regulation of extracellular matrix |
| Experiment | prostate cancer Vs normal prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 30 normal tissue samples compared with 30 cancerous tissue samples using RT-PCR. 5 normal tissue samples compared with 5 cancerous tissue samples using Western Blot Analysis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | GOLM1 |